A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
Primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma that usually occurs in HIV-positive patients and has a very poor prognosis with limited treatment options. Prospective studies are lacking to define the standard of care for this disease, and various case series report median survival at 6 months with anthracycline-based chemotherapy. Reports of antiviral agents, immune modulators, and some targeted therapies are present in the literature with variable results. Herein, we report a case of an elderly HIV-negative man of Mediterranean origin who was diagnosed with primary effusion lymphoma and responded dramatically to 6 cycles of a combination of bortezomib, pegylated liposomal doxorubicin, and rituximab. He has since been maintained on rituximab and remains in complete remission 2 years after diagnosis. In this report, we discuss the rationale for using these agents in this patient and advocate the further study of bortezomib-based therapy in PEL.
Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Tanya
T
Siddiqi
Robin M
RM
Joyce
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D004317:Doxorubicin / Q000008:administration & dosage; D006678:HIV; D006566:Herpesviridae Infections / Q000503:physiopathology; D019288:Herpesvirus 8, Human; D006801:Humans; D007150:Immunohistochemistry; D008081:Liposomes; D054685:Lymphoma, Primary Effusion / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D049268:Positron-Emission Tomography; D011719:Pyrazines / Q000008:administration & dosage; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D008081:Liposomes; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; D004317:Doxorubicin